Karina Gravgaard Thomsen

Author

Also Known As

K. Thomsen, Karina G. Thomsen, Karina Gravgaard, Karina Gravgaard Thomsen, Karina H. Gravgaard, P. Pfeiffer, Thomsen, Karina Gravgaard

Publications

632

Citations

H-Index

Concepts

All Affiliations

Odense University Hospital University of Southern Denmark Slagelse Hospital Rigshospitalet Copenhagen University Hospital

About

Karina Gravgaard Thomsen is an author at Odense University Hospital specializing in medicine, radiation oncology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	353
2	Cell Biology	3	3	129
3	Pathology	2	2	246
4	Immunology	1	1	22
5	Cancer Cell Biology	1	1	22

Karina Gravgaard Thomsen

Publications

611

Citations

H-Index

Page 1

	Year	Citations
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial Per Pfeiffer, Mette Yilmaz, Sören Möller, The Lancet Oncology Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2020	224
Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study Annette Raskov Kodahl, Maria Lyng, Harald Binder, Molecular Oncology	2014	185
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer Karina Gravgaard Thomsen, Maria Lyng, Anne‐Vibeke Lænkholm, Breast Cancer Research and Treatment Breast OncologyMetastatic TissueBreast CancerMirna-200 FamilyMicrorna Detection	2012	96
Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study Maria Lyng, Anne‐Vibeke Lænkholm, Rolf Søkilde, PLoS ONE	2012	60
miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization<i>in vivo</i>and causes significant signaling alterations Karina Gravgaard Thomsen, Mikkel G. Terp, Rikke Raaen Lund, Oncotarget ImmunologyPathologyCancer BiologyTumor BiologyGlobal Mirna Profiling	2015	22
Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study Maria Lyng, Anne‐Vibeke Lænkholm, Qihua Tan, PLoS ONE	2013	13
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients Karina Gravgaard Thomsen, Maria Lyng, Daniel Eliáš, Breast Cancer Research and Treatment Breast OncologyMedicineGene Expression AlterationsCancer GenomicsBreast Cancer	2015	11

Page 1